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Abstract
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It has long been recognized that generalized deficits in cognitive ability represent a core
component of schizophrenia, evident prior to full illness onset and independent of medication. The
possibility of genetic overlap between risk for schizophrenia and cognitive phenotypes has been
suggested by the presence of cognitive deficits in first-degree relatives of patients with
schizophrenia; however, until recently, molecular genetic approaches to test this overlap have
been lacking. Within the last few years, large-scale genome-wide association studies (GWAS) of
schizophrenia have demonstrated that a substantial proportion of the heritability of the disorder is
explained by a polygenic component consisting of many common SNPs of extremely small effect.
Similar results have been reported in GWAS of general cognitive ability. The primary aim of the
present study is to provide the first molecular genetic test of the classic endophenotype hypothesis,
which states that alleles associated with reduced cognitive ability should also serve to increase risk
for schizophrenia. We tested the endophenotype hypothesis by applying polygenic SNP scores
derived from a large-scale cognitive GWAS meta-analysis (~5000 individuals from 9 non-clinical
cohorts comprising the COGENT consortium) to four schizophrenia case-control cohorts. As
predicted, cases had significantly lower cognitive polygenic scores compared to controls. In
parallel, polygenic risk scores for schizophrenia were associated with lower general cognitive
ability. Additionally, using our large cognitive meta-analytic dataset, we identified nominally
significant cognitive associations for several SNPs that have previously been robustly associated
with schizophrenia susceptibility. Results provide molecular confirmation of the genetic overlap
between schizophrenia and general cognitive ability, and may provide additional insight into
pathophysiology of the disorder.
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Schizophrenia (SCZ) is a brain disorder characterized by, on average, a reduction in general
cognitive abilities of >1 SD below the population mean. Given the long-standing
observation of subtle cognitive abnormalities in undiagnosed and unmedicated relatives of
patients with SCZ, it has been suggested that cognitive deficits may serve as an
endophenotype, permitting identification of SCZ risk genes using a quantitative phenotype
more closely reflecting gene function.1 Extensive family and twin data support the role of
shared additive genetic factors underpinning both SCZ and cognitive deficits.2 A recent
population-scale study of siblings and twins further suggested that the overlap between these
phenotypes is largely genetic, but questioned the overall magnitude of the phenotypic
correlation.3 However, these family-based studies have two primary limitations: 1) they lack
direct molecular assays of genetic variance, and 2) they have relied upon measurement of
cognitive abilities in patients with SCZ, which are subject to potential confounds relating to
illness process and state.

Author Manuscript

A direct test of the endophenotype hypothesis would examine molecular genetic variants
associated with cognitive performance in the general (not clinically-referred) population, in
order to see if these variants are also associated with SCZ. However, this approach has not
been adequately tested due to the lack of strongly replicated cognition-associated single
nucleotide polymorphisms (SNPs). By contrast, a number of candidate gene studies have
applied a “reverse endophenotype” approach, in which SCZ risk variants are tested for
association with cognition in the general population.4,5

Author Manuscript

Large-scale genome-wide association studies (GWAS) of schizophrenia have demonstrated
that a substantial proportion of the heritability of the disorder is explained by a polygenic
component consisting of thousands of common SNPs of extremely small effect.6 Similarly,
recent GWAS of general cognitive ability have indicated that a polygenic architecture
accounts for a majority of the heritability, consistent with other normally-distributed traits in
the general population, such as height.7–9 The relationship of the underlying genetic
architecture between two phenotypes can be examined using polygenic score tests, in which
large numbers of alleles demonstrating subtle (not statistically significant) levels of
association with a given phenotype are combined to produce a genetic risk profile.10 The
association of these alleles in a different cohort (measured on a different phenotype), can
then be utilized to estimate the degree of molecular overlap between phenotypes.
Very recently, two reverse endophenotype studies have examined the ability of
schizophrenia polygenic risk scores to predict cognitive abilities in independent cohorts.11,12
Both studies draw from the work of the Psychiatric GWAS Consortium on Schizophrenia
(PGC-SCZ), a large-scale mega-analytic GWAS of 17 Caucasian cohorts encompassing
>9000 SCZ cases and >12,000 controls.13 In one study12, polygenic risk scores for SCZ
were significantly associated with IQ in a cohort of patients with SCZ and controls, but
Mol Psychiatry. Author manuscript; available in PMC 2014 August 01.
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these associations were not observed in the smaller (n=322) healthy cohort alone. However,
in a much larger study11, polygenic risk scores for SCZ were found to be significantly
associated with general cognitive ability (as assessed by the first principal component of
cognitive tests assessing multiple domains) in two moderately-sized (total N~1500) cohorts
of psychiatrically normal older adults.

Author Manuscript

In this study, we sought to test the endophenotype hypothesis by comparing SCZ cases to
controls on polygenic SNP scores derived from a large-scale meta-analysis of cognitive
GWAS. We focused on general cognitive ability as the primary endophenotype for several
reasons, which we have discussed in detail previously.14 While a variety of specific
cognitive traits have been proposed as SCZ endophenotypes, research to date has failed to
conclusively demonstrate any specific cognitive signature of schizophrenia.15 Overall,
deficits in general cognitive ability follow the pattern required of an endophenotype1: they
are observed in SCZ patients prior to illness onset, are largely independent of clinical state
and medication status, and are familial in nature.16,17

Author Manuscript

It has been recognized for more than 100 years that most cognitive abilities in humans are
not orthogonal traits, but tend to covary; the underlying factor accounting for this pattern of
intercorrelation is termed general cognitive ability (or Spearman’s g).18 General cognitive
ability is a robust phenotype, accounting for nearly half of the variance on the broad range of
specific neurocognitive traits identifiable in humans.19 Moreover, general cognitive ability
in the population is itself highly heritable,9,20,21 and heritability studies have demonstrated
substantial genetic overlap across most specific cognitive domains tested.18,19,21 Crucially,
general cognitive ability can be reliably estimated by extracting the first principal
component of any appropriately diverse set of neurocognitive test scores, regardless of the
specific components of the battery; it has been empirically demonstrated that estimates of g
derived from varying batteries tend to be very highly correlated, with correlation coefficients
often approaching 1.22,23

Author Manuscript

The present study represents the first empirical report of an international collaborative effort
entitled, “The Cognitive Genomics Consortium (COGENT).”14 COGENT aims to bring
together human genetic datasets with both: 1) high-density genome-wide genotype data and
2) phenotype data on cognitive function in individuals drawn from the general population.
At the time of the first data freeze, COGENT consists of nine sites across 7 countries, with
approximately 5000 individuals with available genotype and phenotype data. Although
genotyping platforms and phenotype measures vary by site, genetic imputation and factor
analysis of cognitive scores were used to harmonize data across sites. Because generalized
cognitive ability (g) can be robustly estimated from a variety of test batteries, we were able
to perform meta-analysis of GWAS associations to g across the nine COGENT cohorts.
From this meta-analysis, we derived polygenic allele scores associated with general
cognitive ability. These allele scores were then applied to four SCZ case-control cohorts
consisting of more than 11,000 independently ascertained subjects (>5000 cases and >5000
controls), as described in detail below. We additionally performed “reverse endophenotype”
analyses, examining the effects of schizophrenia risk alleles (derived from PGC-SCZ) on
cognitive scores in the 9 COGENT cohorts.
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MATERIALS AND METHODS
Subjects – Cognitive GWAS cohorts
Volunteers for cognitive studies were drawn from nine cohorts, for which study
investigators agreed to share data as part of the Cognitive Genomics Consortium
(COGENT). Details on subject recruitment procedures for each cohort are described in the
Supplementary Materials; summaries of each cohort are presented in Table 1. Although
screening procedures differed somewhat across cohorts, subjects were drawn from the
general population, either as epidemiologically representative cohorts or as recruited control
cohorts for studies of schizophrenia and/or other mental illnesses. All subjects were of
Caucasian descent (as confirmed by principal components analysis of genetic data). All
subjects provided written, informed consent to protocols approved by their institutional
ethics boards in accordance with the Helsinki declaration.

Author Manuscript

Subjects – Schizophrenia case-control cohorts

Author Manuscript

The primary test of the endophenotype hypothesis was performed in the Molecular Genetics
of Schizophrenia (MGS) European-American case-control cohort. This dataset was selected
for several reasons: it is large (n>5000), publicly available, has been extensively
studied,24–26 and contains an ethnic distribution that is comparable to our nine COGENT
cohorts (primarily Northern European in ancestry but with a non-negligible Southern
European component as well). To replicate and extend our findings, we secondarily tested
three additional SCZ case-control cohorts of varying ethnicities: 1) A Japanese cohort with
>1000 subjects;27 2) An Ashkenazi Jewish cohort with >2500 subjects;28 and the AfricanAmerican subcohort (n>2000) of the MGS sample.25 Demographic details of these cohorts
are presented in Table 2. It should be noted that increasing evidence suggests substantial
common architecture of complex traits (including schizophrenia) across populations,29,30
but it would still be anticipated that replication samples would demonstrate attenuated effect
sizes due to residual differences in allele frequencies and effect sizes.31
Genotyping, quality control, and imputation

Author Manuscript

As described in detail in the Supplementary Materials, all COGENT subjects were
genotyped on one of three microarray platforms: Affymetrix 6.0 (~900K SNPs), Illumina
610K, or Illumina OmniExpress (~770K SNPs). A standardized quality control pipeline was
applied to each COGENT GWAS dataset: SNP call rate > 95%; sample call rate > 90%;
SNP Hardy-Weinberg equilibrium (HWE) p>10−6; and X chromosome sex match with
reported gender. For any pair of subjects with cryptic relatedness (pi-hat>.125 in PLINK32
1.07), the sample with the lower call rate was eliminated. For each dataset, a principal
components analysis was performed (in SVS 7.7.4, GoldenHelix Inc., Bozeman, MT), and
samples demonstrating non- Caucasian ancestry were eliminated.
After QC, all SNPs within a given cohort were strand-aligned to HapMap3 and phased using
SHAPEIT33 prior to imputation with IMPUTE2.34 As recently recommended to increase
imputation accuracy,35 a large, cosmopolitan HapMap3 reference panel (n=1,011
individuals from Africa, Asia, Europe, and the Americas) was utilized (except for NCNG,
which was the only dataset for which imputation was not performed centrally). Because our
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phenotype is a quantitative trait, we sought to avoid potentially spurious findings introduced
by random association of rare alleles with a few extreme scores.36 Therefore, imputed SNPs
receiving a probability call >.90 were retained and converted to PLINK-format genotype
calls. The imputed data were then recleaned using the same call rate and HWE criteria
described above; additionally, SNPs with minor allele frequency <2.5% were dropped. For
each cohort, ~3000 randomly selected genotyped SNPs were held out for concordance
analysis with imputation results. As shown in Table 1, concordance exceeded 99% for seven
COGENT cohorts, and ~1M SNPs were available for analysis in each cohort.
Neurocognitive assessment

Author Manuscript

Details of neurocognitive batteries for each cohort are provided in the Supplementary
Materials. While the specific instruments varied across cohorts, each cohort was required to
have test scores available across at least 3 domains of cognitive ability for computation of
Spearman’s g,18,37 an estimate of general cognitive ability derived from principal
components analysis (PCA).22,23 (For one cohort, a validated estimate of general cognitive
ability derived from two subscales of the Wechsler Adult Intelligence Scale was utilized.)
For each of the cohorts, available measures were entered into PCA and the first unrotated
component was extracted. Any variable with more than 5% of missing data was dropped
from the analysis. Normality is not a strict requirement of principal components analysis
implemented for the purpose of data reduction and so no variable was subject to
transformation.38 Moreover, inspection of box plots indicated that variables were generally
normally distributed and no noticeable outliers were observed. In each cohort, as expected
based on hundreds of prior studies,39 the first principal component significantly loaded all
measures and accounted for ~40% of the variance on average.

Author Manuscript

The dependent measure for the cognitive GWAS in each cohort was this first PC score,
corrected for the following (using linear regression prior to GWAS): age, sex, age*sex, age2,
and age2*sex, based on consistent evidence demonstrating the presence of both linear and
quadratic effects of age on general cognitive ability across the lifespan40.
Statistical analysis

Author Manuscript

Genome-wide association analysis of the quantitative cognitive phenotype was performed in
each COGENT cohort using linear regression (additive model) in SVS7.7.4. As shown in
Table 1, lambda (genomic control) values for each cohort were at or near 1, indicating no
significant effect of subtle population structure on association results. Fixed effects metaanalysis of β weights from the linear regression analyses was performed in PLINK 1.0732
using data from all available cohorts possessing high-QC genotyped or imputed data for
each given SNP. Only SNPs with data available in 3 or more cohorts were retained. By
convention, a positive β weight for a given allele indicated an additive (allele-dose)
relationship in the direction of higher cognitive phenotype scores.
Based on results of the meta-analysis, polygenic scores were computed in PLINK using β
weights of alleles at varying statistical thresholds (nominal p<.10, .20, .30, .40, and .50)
following the procedure originally described by Purcell et al.10 For each statistical threshold,
the clump procedure in PLINK was utilized to prune the set of SNPs for linkage
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disequilibrium (using r2 threshold of .50 within a 250kb window), so as to avoid redundancy
of SNPs representing a given association signal.
For each of the five statistical thresholds, the weighted allele scores of each “clumped” SNP
were summed for each subject in each SCZ case-control cohort, thus creating a “cognitive
polygene score.” Thus, each subject in each SCZ case-control dataset had a set of 5
cognitive polygene scores: one for each of the statistical thresholds applied to the original
COGENT meta-analytic results. For each SCZ case-control dataset, five logistic regression
analyses were then used to compare cases and controls on cognitive polygene scores at each
threshold. Nagelkerkes’ pseudoR2 was utilized to reflect estimated percent variance in the
SCZ phenotype accounted for by cognitive polygene scores at each threshold.10

RESULTS
Author Manuscript

GWAS results for general cognitive ability
Meta-analytic results of the nine cognitive GWAS cohorts are presented as a Manhattan plot
in Figure 1; no SNPs reached genomewide significance, and the overall lambda was 1.031
(see QQ plot in Supplementary Figure 1). This lambda value is higher than that for any
individual cohort (Table 1), indicative of polygenic signal41, but is lower than reported in
similar recent studies of cognitive ability7,9. A list of top SNPs (p<.001) emerging from the
meta-analysis are presented in Supplementary Table 1.
Primary test of endophenotype hypothesis – cognitive polygenic score analysis

Author Manuscript

We utilized a large, publicly available, Caucasian SCZ GWAS case-control cohort to test
our primary endophenotype hypothesis. Using “clumped” SNPs at 5 different thresholds
(nominal p<.10, .20, .30, .40, and .50), polygenic cognitive scores were computed for each
of 2886 cases and 2056 controls in the MGS/GAIN European-American cohort. As
predicted, cases had significantly lower cognitive polygenic scores across each of the five
thresholds (p-values ranging from 6.56*10−6 to 3.73*10−7; see Figure 2). In other words,
SCZ cases had fewer alleles associated with good cognitive performance and more alleles
associated with poorer cognitive performance in the COGENT meta-analysis. The overall
magnitude of the polygenic effect was small (R2<.01), but comparable to the total variance
explained by a similar approach applied from one cognitive cohort to another7 and from a
reverse endophenotype study.11

Author Manuscript

As replication, the same cognitive SNPs were tested in three smaller SCZ case-control
cohorts of differing ethnicities. Because of the apparent dip in variance explained that
appears at p<0.2 in the MGS EA cohort (Figure 1), we applied a p<0.3 threshold in our
replication datasets. As depicted in Table 3, nominally significant results were observed in
two cohorts (Japanese and Ashkenazi Jewish). Meta-analysis of these results across the four
SCZ case-control cohorts yielded a strongly significant effect of cognitive polygenic scores
on prediction of schizophrenia risk (p=3.6*10−7). Very similar results were observed using a
clump threshold of p<0.5 (Supplementary Table 2; meta-analytic p=3.8*10−7), and
somewhat stronger results were observed when the IBG cohort (the only non-adult
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COGENT cohort) was removed prior to calculation of polygenic allele weights
(Supplementary Table 3; meta-analytic p=4.0*10−9).
Reverse endophenotype approach – examination of prior schizophrenia GWAS hits

Author Manuscript

As an additional examination of the relationship between cognitive GWAS results and the
schizophrenia phenotype, we applied the commonly-employed “reverse endophenotype”
approach described above. First, we selected all SNPs that have demonstrated genomewide
significance (p<5*10−8) in large-scale (total n>5000) published SCZ GWAS obtained from
the NHGRI GWAS catalog (http://www.genome.gov/gwastudies/, downloaded Jan. 10,
2013). As shown in Table 4, four of the 13 independent SNPs (excluding the major
histocompatibility complex) associated with schizophrenia have nominally significant (p<.
05) associations with general cognitive ability in volunteers from the general population.
While effect sizes for these SNPs on cognitive phenotypes are extremely modest, the
number of SNPs achieving nominal significance exceeded that expected by chance
(binomial test, p=.006, two-tailed). Although extensive linkage disequilibrium in the MHC
has prohibited clear discernment of the source of SCZ GWAS signal, supplementary Table 4
demonstrates results for 5 SNPs in the region derived from published SCZ GWAS.
Reverse endophenotype approach – schizophrenia susceptibility polygenic score analysis

Author Manuscript

Finally, we performed a polygenic score analysis, comparable to the one presented in Table
2, but in the “reverse” direction. Specifically, we downloaded “clumped” SNPs derived from
the publicly-available PGC13 dataset (https://pgc.unc.edu/Sharing.php#SharingOpp).
Because polygenic score approaches to schizophrenia have tended to demonstrate increasing
variance explained at higher p-value thresholds10, we utilized a threshold of p<.50 on the
resulting clumped SNPs. These polygenic scores were then computed for each subject in
each of the 9 COGENT cohorts separately; scores were then compared to cognitive ability
(g) using linear regression in each cohort. As shown in Table 5, schizophrenia-derived
polygenic scores were correlated with cognitive ability in the predicted direction (greater
schizophrenia load associated with lower cognitive scores) in 7 of the 9 cohorts, with three
cohorts demonstrating nominally significant (or nearly so) results. As with the primary
analysis, total variance accounted for was small (R2 range from 0–2%) but strongly
significant (p=1.4*10−4) in the combined analysis.

DISCUSSION

Author Manuscript

To our knowledge, this is the first study to present molecular genetic evidence supporting
general cognitive ability as a true endophenotype for schizophrenia susceptibility. In a large
Caucasian SCZ case-control cohort, we demonstrated that a set of polygenic alleles
associated with lower general cognitive ability strongly predicted increased likelihood for
the disorder. Consistent, though less strong, associations were observed in additional
cohorts, despite the fact that they were drawn from populations of differing ethnicities.
While the statistical evidence (p-values ranging from ~10−6 to ~10−9) for association was
strong, the overall amount of variance explained, even in the Caucasian SCZ cohort (~0.5%)
was modest, a result that must be interpreted in the context of other studies of polygenic
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overlap. For example, in a recent study of cognition,7 polygenic SNP scores accounted for
only ~1% of the variance in a separate cognitive cohort (these cohorts are now included in
COGENT). Nevertheless, these authors were able to demonstrate that nearly half of the
variation in cognitive ability could ultimately be accounted for by common SNPs. Similarly,
the initial study of polygenic effects in schizophrenia identified only ~2–3% overlap
between any two schizophrenia cohorts, and ~1–2% overlap between schizophrenia and
bipolar cohorts.10 Again, extensive simulations demonstrated that the polygenic SNPs
tagged common genetic variation accounting for approximately one-third of the total
variance in SCZ risk; this estimate has been replicated, indicating that the empirically
observed cross-sample allelic overlap is a substantial under-estimate of the total polygenic
effect.6 Moreover, observed polygenic overlap tends to rapidly increase as a function of
sample size; for example, the empirically observed variance explained by polygenic effects
in schizophrenia has increased tenfold with larger sample sizes.42 While the COGENT
cohort represents the largest genetic sample of cognition to date, sample size remains small
relative to polygenic studies of other quantitative traits such as height.43,44

Author Manuscript

Thus, the results of the present study are consistent with a model in which a substantial
fraction of the molecular basis of general cognitive ability is shared with genetic risk for
schizophrenia. These results are consistent with a large body of evidence from family-based
studies which use twin and sibling correlations to model genetic effects.2 While a recent
population-based study using similar modeling strategies3 found only limited phenotypic
overlap between intelligence and psychosis, the source of this overlap was estimated to be
largely (~90%) comprised of additive genetic variation. The present study is unique in
directly testing molecular genetic variation, and utilizing non-clinical volunteers for the
estimation of the cognitive genetic component. Our demonstration of parallel effects when
examining genomewide overlap in the reverse direction (SCZ risk alleles predicting
cognitive scores, Table 5) add further confidence to our conclusions, and are also consistent
with a recent genomewide reverse endophenotype study, which demonstrated significant
overlap between polygenic SCZ risk alleles and cognitive decline in two aging cohorts.11

Author Manuscript

Additionally, following the conventional “reverse endophenotype” approach, multiple
GWAS-identified SCZ risk SNPs (4/13, or 31%) demonstrated nominal evidence of
association to general cognitive ability in a large meta-analytic cohort of non-clinical
volunteers. Three of these are intronic SNPs, in MAD1LI, LSM1, and CNNM2, and the
present study represents the first report of human neurocognitive correlates of variants at
these loci. Little is known about the functions of these genes in the central nervous system,
and the structural and functional properties of their associated proteins vary widely. The
fourth nominally significant locus is less than 5kb 5’ to NRGN (and is in an LD block
encompassing the gene). NRGN encodes neurogranin, a well-characterized postsynaptic
protein which binds to calmodulin and thereby modulates postsynaptic calcium signaling.45
Although this locus did not show significant association with cognitive variables in a smaller
prior study,46 neuroimaging studies have previously associated this locus with structural and
functional variation in the frontal cortex, cingulate, and hippocampus.47–50 Although these
results were significant in the aggregate (p=.006 by binomial test), it should be emphasized
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that the effect sizes for individual SNPs were extremely small, and p-values would not
survive Bonferroni correction.
Based on the present results, it is likely that larger sample sizes will afford greater ability to
predict schizophrenia using cognitive polygenic scores. This overlap can then be utilized to
enhance schizophrenia gene detection using recently developed “pleiotropic enrichment”
techniques.51 At the same time, the study of the genetic basis of normal variation in
cognition is likely to further our understanding of the mechanisms by which schizophrenia
risk genes affect the central nervous system.

Author Manuscript

Several caveats should be placed on the interpretation of this study. First, the present study
did not directly evaluate the genetic source of cognitive deficits in patients with
schizophrenia. It could be argued that GWAS of cognitive ability in schizophrenia cohorts
would be required to test whether this putative endophenotype actually mediates the
relationship between cognitive polygene score and schizophrenia risk. However, cognitive
performance in patients with schizophrenia can be influenced by potential confounds such as
effects of medication or acute symptomatology, which would tend to attenuate any genetic
signal. Consequently, our approach of utilizing non-clinical samples was designed to
maximize the potential power of GWAS.

Author Manuscript

Finally, it should be noted that no genomewide significant loci for cognition were identified
in the present study, despite being the largest GWAS of cognitive ability in predominately
adult cohorts. This result was anticipated based on recent large-scale GWAS results for
childhood intelligence9, as well as early GWAS (with comparable sample size to the present
study) of potentially comparable quantitative traits, height52 and weight53. It is also possible
that power to detect genetic signals was reduced due to unavoidable heterogeneity in
cognitive assessment methods across cohorts; such an interpretation is consistent with the
relatively low lambda observed in our study. Future studies, ideally with prospectively
collected cohorts utilizing harmonized approaches to phenotype assessment, will be required
to tease out genomewide significant loci for cognitive ability.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Manhattan plot depicting results of COGENT meta-analysis.
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Figure 2.
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Polygenic overlap between cognitive allele scores (derived from COGENT metaanalysis
thresholded at varying p-values) and schizophrenia (SCZ) case-control status in the MGS
European-American cohort.
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Table 1

Author Manuscript

Description of COGENT cohorts.
Dataseta

Genotyping
Platform

Concordanceb

Genotypes
after QC

N

%Male

Mean Age (SD)

Lambdac

Germany

Illumina OE d

99.50%

1,078,289

594

51%

54.0 (15.0)

1.01

LOGOS

Illumina OE

99.40%

835,287

802

100%

22.3 (3.8)

1.03

IBG

Affymetrix 6.0

99.59%

938,800

299

77%

15.9 (1.5)

1.00

LBC1936

Illumina 610

99.60%

1,058,722

1005

51%

69.5 (0.8)

1.01

TOP

Affymetrix 6.0

94.23%

917,315

351

48%

34.2 (9.8)

1.01

NCNG

Illumina 610

99.40%

944,135

629

32%

47.6 (18.3)

1.00

Manchester

Illumina 610

99.60%

1,059,916

697

30%

67.7 (2.8)

1.01

HBCS

Illumina 610

99.60%

1,043,380

318

100%

67.7 (2.3)

1.00

ZHH

Illumina OE

99.40%

1,043,785

201

47%

39.1 (1.8)

1.06

Author Manuscript

a

Detailed descriptions of each cohort provided in Supplementary Text.

b

Concordance between imputed and genotyped SNPs.

c

Lambda to refers λGC,, a measure of the degree of statistical inflation in genomewide association studies.

d
OE refers to the Illumina OmniExpress genotyping bead chip
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Author Manuscript

Description of schizophrenia case-control cohorts.
SCZ Dataset

N Cases

N Controls

GWAS platform

MGS European-American Shi et al. 2009

2681

2653

Affymetrix 6.0

Japan Ikeda et al. 2011

575

564

Affymetrix 5.0

Ashkenazi Jewish (Israel) Guha et al. 2013

904

1640

Illumina Omni1-Quad

MGS African-American Shi et al. 2009

1286

973

Affymetrix 6.0

Total

5446

5830
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Table 3

Author Manuscript

Polygenic overlap between cognitive alleles (derived from COGENT meta-analysis using p<0.3 threshold)
and schizophrenia in four case-control cohorts.
SCZ Dataset

# overlapping SNPs

R2 for SCZ

p value

direction

MGS European-American

17,237

0.41%

1.3*10−6

negative

Japan

6,468

0.38%

0.039

negative

Ashkenazi Jewish

15,151

0.16%

0.041

negative

MGS African-American

17,382

0.00%

0.958

positive

3.6*10−7

negative

Meta-analysis
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Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript
rs10503253
rs16887244
rs7914558
rs11191580
rs12807809
rs12966547

Ripke (PGC) Nat Gen 2011

Shi (China) Nat Gen 2011c

Ripke (PGC) Nat Gen 2011b

Ripke (PGC) Nat Gen 2011

Decode Nature 2009c

Ripke (PGC) Nat Gen 2011

18q21.2

11q24.2

10q24.33

10q24.32

8p11.23

8p23.2

7p22.3

TCF4

NRGN

NT5C2

CNNM2

LSM1

CSMD1

MAD1L1

ZSWIM6

PCGEM1

ZNF804A

SDCCAG8

MPC2

MIR137

Gene

schizophrenia risk allele associated with higher cognitive ability

c

rs12666575

Bergen (Swe) Mol Psy 2012b

5q12.1

2q32.3

2q32.1

1q43

1q24.2

1p21.3

Region

schizophrenia risk allele associated with lower cognitive ability

b

rs7709645

Bergen (Swe) Mol Psy 2012

based on source publication

a

rs17662626

rs6703335

Ripke (PGC) Nat Gen 2011
rs1344706

rs10489202

Shi (China) Nat Gen 2011

Ripke (PGC) Nat Gen 2011

rs1625579

Ripke (PGC) Nat Gen 2011

O’Donovan Nat Gen 2011

SNP

Source

0.58

0.83

0.91

0.59

0.683

0.19

0.673

0.475

0.91

0.59

0.56

0.141

0.8

Risk Allele
Freqa

1.4

1.15

1.2

1.22

1.19

1.16

1.12

1.11

1.2

1.12

1.09

1.23

1.12

OR_Sza

8

8

9

9

9

7

8

9

5

9

6

9

8

COGENT
studies

0.7327

0.0399

0.6575

0.0368

0.0171

0.5874

0.0320

0.7207

0.4509

0.4048

0.9127

0.9024

0.4789

P_COGENT
meta-analysis

Examination of cognitive associations (in COGENT meta-analysis) for SNPs identified in published GWAS for schizophrenia (excluding MHC).
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Table 5

Author Manuscript

Polygenic overlap between schizophrenia risk alleles (derived from PGC meta-analysis using p<0.5 threshold)
and general cognitive ability in nine COGENT cohorts.

Author Manuscript

# overlapping
SNPs

R2 for g

p value

Germany

89,360

0.08%

0.475

Positive

LOGOS

69,069

0.00%

0.985

Positive

IBG

89,353

0.04%

0.72

Negative

LBC1936

96,820

1.17%

0.0006

Negative

TOP

88,946

0.10%

0.5481

Negative

NCNG

87,934

0.04%

0.5925

Negative

Manchester

96,907

1.61%

0.0007

Negative

HBSC

93,890

0.11%

0.5467

Negative

ZHH

85,681

1.90%

0.0532

Negative

1.4*10−4

negative

COGENT Dataset

Meta-analysis

Direction
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